In last trading session, Skye Bioscience Inc (NASDAQ:SKYE) saw 76133.0 shares changing hands with its beta currently measuring 1.72. Company’s recent per share price level of $4.26 trading at -$0.02 or -0.47% at ring of the bell on the day assigns it a market valuation of $129.24M. That closing price of SKYE’s stock is at a discount of -355.63% from its 52-week high price of $19.41 and is indicating a premium of 66.2% from its 52-week low price of $1.44. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.17 million shares which gives us an average trading volume of 314.37K if we extend that period to 3-months.
For Skye Bioscience Inc (SKYE), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.29 in the current quarter.
Skye Bioscience Inc (NASDAQ:SKYE) trade information
Upright in the red during last session for losing -0.47%, in the last five days SKYE remained trading in the red while hitting it’s week-highest on Thursday, 11/21/24 when the stock touched $4.26 price level, adding 5.12% to its value on the day. Skye Bioscience Inc’s shares saw a change of 56.62% in year-to-date performance and have moved -0.47% in past 5-day. Skye Bioscience Inc (NASDAQ:SKYE) showed a performance of -18.39% in past 30-days. Number of shares sold short was 1.99 million shares which calculate 9.41 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 20 to the stock, which implies a rise of 78.7% to its current value. Analysts have been projecting 15 as a low price target for the stock while placing it at a high target of 21. It follows that stock’s current price would drop -252.11% in reaching the projected high whereas dropping to the targeted low would mean a loss of -252.11% for stock’s current value.
Skye Bioscience Inc (SKYE) estimates and forecasts
Statistics highlight that Skye Bioscience Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -63.43% of value to its shares in past 6 months, showing an annual growth rate of 82.12% while that of industry is 17.60. Apart from that, the company came raising its revenue forecast for fiscal year 2024.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 32.94% during past 5 years.
Skye Bioscience Inc (NASDAQ:SKYE)’s Major holders
Insiders are in possession of 1.32% of company’s total shares while institution are holding 86.02 percent of that, with stock having share float percentage of 87.17%. Investors also watch the number of corporate investors in a company very closely, which is 86.02% institutions for Skye Bioscience Inc that are currently holding shares of the company.
